Treatment Options for Nasal Congestion

First-Line Treatments

• The American Academy of Allergy, Asthma, and Immunology recommends intranasal corticosteroids as the most effective monotherapy for nasal congestion associated with allergic rhinitis, with an onset of action usually within 12 hours 1
• Intranasal corticosteroids are effective for all symptoms, including nasal congestion, with minimal side effects, and are more effective than a combination of oral antihistamine and leukotriene receptor antagonists 1
• Topical decongestants are appropriate for short-term (3-5 days maximum) and episodic therapy of nasal congestion, providing rapid relief through nasal vasoconstriction and decreased nasal edema 2, 3, 4

Second-Line Treatments

• Oral decongestants, such as pseudoephedrine, effectively reduce nasal congestion, but are associated with small increases in systolic blood pressure and heart rate, and should be used with caution in patients with hypertension, arrhythmias, or coronary artery disease 2, 3, 4
• Second-generation oral antihistamines, such as loratadine and fexofenadine, are less sedating than first-generation antihistamines, but are less effective for nasal congestion than for other nasal symptoms 1

Additional Options

• Nasal saline irrigation provides symptomatic relief with minimal risk of adverse effects, and is particularly useful for drug-induced nasal congestion 5
• Leukotriene receptor antagonists, such as montelukast, have similar efficacy to oral antihistamines, and may be considered in patients with both rhinitis and asthma 1
• Intranasal anticholinergics, such as ipratropium bromide, reduce rhinorrhea, but not other symptoms, and can be combined with intranasal corticosteroids for enhanced effect on rhinorrhea 1, 6

Special Considerations

• The American College of Allergy, Asthma, and Immunology recommends caution with decongestants during the first trimester of pregnancy due to reported fetal heart rate changes 4
• Topical decongestants should be used with care in children under 1 year due to a narrow therapeutic window 4

Treatment Algorithm

• For allergic rhinitis with congestion, the American Academy of Allergy, Asthma, and Immunology recommends starting with intranasal corticosteroids as first-line therapy, and adding an intranasal antihistamine if symptoms persist 1, 6
• For acute congestion, short-term topical decongestant (3-5 days maximum) is recommended, with consideration of oral decongestant if topical therapy is contraindicated 2

Decongestant Therapy for Nasal Congestion

Oral Decongestants

• The American Academy of Allergy, Asthma, and Immunology recommends pseudoephedrine 60 mg every 4-6 hours as the only oral decongestant with proven efficacy, while phenylephrine should be avoided due to extensive first-pass metabolism rendering it ineffective at standard doses 7
• Pseudoephedrine reduces nasal congestion in both allergic and nonallergic rhinitis, with documented efficacy using objective measures of nasal airway resistance 8
• Monitor blood pressure in hypertensive patients taking pseudoephedrine, though elevation is rarely noted in normotensive patients and only occasionally in those with controlled hypertension 8, 9
• Use pseudoephedrine with extreme caution or avoid entirely in patients with arrhythmias, angina pectoris, coronary artery disease, cerebrovascular disease, and hyperthyroidism 7

Topical Decongestants

• For rapid relief of severe nasal congestion, prescribe oxymetazoline 0.05% nasal spray, but strictly limit use to 3 days maximum to prevent rhinitis medicamentosa 7, 8
• Topical decongestants provide superior efficacy for nasal decongestion compared to intranasal corticosteroids, with onset within minutes 7
• Instruct all patients about the risk of rhinitis medicamentosa when using topical decongestants beyond 3 days 7, 8
• Use topical decongestants with caution during the first trimester of pregnancy due to reported fetal heart rate changes 7
• Use topical decongestants with care in children under 1 year due to narrow therapeutic window and increased risk of cardiovascular and CNS side effects 7

Alternative First-Line Therapy

• For patients requiring ongoing treatment of nasal congestion, particularly with allergic rhinitis, prescribe intranasal corticosteroids as first-line therapy rather than decongestants 8
• Intranasal corticosteroids are the most effective medication class for controlling all four major symptoms of allergic rhinitis, including nasal congestion 8, 9

Combination Therapy

• Oral decongestants are beneficial when combined with antihistamines for comprehensive symptom relief in allergic rhinitis 8, 9

Antihistamine-Decongestant Combinations for Allergic Rhinitis

Primary Recommendation: Second-Generation Combinations

• The American Academy of Allergy, Asthma, and Immunology recommends avoiding first-generation antihistamine/decongestant combinations due to significant sedation, performance impairment, and dangerous anticholinergic effects in patients with allergic rhinitis 10

Critical Cardiovascular Considerations

• The American Heart Association suggests using extreme caution or avoiding pseudoephedrine entirely in patients with arrhythmias, angina pectoris, coronary artery disease, cerebrovascular disease, uncontrolled hypertension, hyperthyroidism, bladder neck obstruction, or glaucoma 10

Alternative First-Line Strategy

• The American Academy of Allergy, Asthma, and Immunology recommends prescribing intranasal corticosteroids as monotherapy instead of any decongestant combination for patients with cardiovascular comorbidities, as they are the most effective monotherapy for all allergic rhinitis symptoms, including nasal congestion, with onset within 12 hours 11

Why Antihistamine Monotherapy Is Insufficient

• The American Academy of Allergy, Asthma, and Immunology notes that second-generation oral antihistamines alone are less effective for nasal congestion than for other nasal symptoms, which is why combination therapy with pseudoephedrine provides additional benefit specifically for congestion 10, 11

Evidence‑Based Management of Nasal Congestion

First‑Line Pharmacotherapy

• Intranasal corticosteroids are the most effective first‑line agents for nasal congestion associated with allergic or chronic rhinitis, producing symptom relief within 12 hours and offering superior sustained efficacy compared with all other medication classes. [12][13]
• Intranasal corticosteroids (e.g., fluticasone, mometasone, budesonide) used as monotherapy control the four major rhinitis symptoms—including congestion—while producing minimal systemic side effects when administered at recommended doses. [12][13]

Administration Technique and Safety Monitoring

• Sprays should be directed away from the nasal septum to avoid local irritation, epistaxis, and the rare risk of septal perforation. [12][13]
• Periodic inspection of the nasal septum is advised to detect any mucosal erosions early. 13

Limits on Topical Decongestant Use

• Topical nasal decongestants must be limited to a maximum of 3 days to prevent rhinitis medicamentosa, which can begin as early as day 3–4 of continuous use. 12

Intranasal Antihistamines

• Intranasal antihistamines may be employed as a first‑line option and provide a clinically meaningful reduction in nasal congestion. 12
• They are at least as effective as, and often superior to, oral second‑generation antihistamines for seasonal allergic rhinitis. 12
• Nevertheless, intranasal antihistamines are generally less effective than intranasal corticosteroids for relieving congestion. 12
• Systemic absorption can cause sedation and may suppress skin‑test reactivity. 12

Intranasal Anticholinergics

• Ipratropium bromide effectively reduces rhinorrhea but does not improve nasal congestion. [12][13]
• When combined with intranasal corticosteroids, ipratropium enhances control of rhinorrhea without adding adverse events. [12][13]

Leukotriene Receptor Antagonists

• Montelukast shows efficacy comparable to oral antihistamines and can be considered for patients who have both rhinitis and asthma. 12

Saline Irrigation

• Nasal saline irrigation, either as a sole therapy or adjunct, provides symptomatic relief for chronic rhinorrhea and rhinosinusitis with minimal risk. 12

Management of Rhinitis Medicamentosa (Rebound Congestion)

• Rebound congestion arises after topical decongestant use exceeding 3 days. 12
• A short course (5–7 days) of oral corticosteroids may be added for very severe or intractable cases to accelerate mucosal recovery. [12][13]

Special Populations

• In children, intranasal corticosteroids should be prescribed at the lowest effective dose. 13
• Elderly patients require cautious use of oral and topical decongestants because of heightened cardiovascular and central‑nervous‑system side‑effect risk. 12

Immunotherapy and Severe/Refractory Cases

• Allergen immunotherapy is recommended for patients with allergic rhinitis who have documented IgE sensitization to relevant allergens. 12
• For very severe or refractory nasal symptoms (including significant nasal polyposis), a short (5–7 day) oral corticosteroid regimen is appropriate. [12][13]

Common Pitfalls to Avoid

• Do not exceed a 3‑day duration of topical nasal decongestants to prevent rhinitis medicamentosa. 12
• Always educate patients to aim sprays away from the septum when prescribing intranasal corticosteroids. [12][13]
• First‑generation antihistamines should be avoided because of pronounced sedation and anticholinergic effects. 12

Management of Nasal Congestion in Down Syndrome Patients

Risks of Sympathomimetic Decongestants

• Oral sympathomimetic decongestants such as pseudo‑ephedrine and phenylephrine should be used only with extreme caution—or avoided entirely—in individuals with Down syndrome who have arrhythmias, angina, coronary artery disease, or cerebrovascular disease, conditions that are markedly more prevalent in this population. 14
• Topical sympathomimetic decongestants (e.g., oxymetazoline) have been associated with rare but serious cerebrovascular events, including stroke, anterior ischemic optic neuropathy, and branch retinal artery occlusion. 14

Guidance on Short‑Term Topical Decongestant Use

• When severe nasal obstruction necessitates rapid relief, a very short course (maximum 3 days) of topical oxymetazoline may be considered only after cardiology clearance in patients with known congenital heart disease. 14
• The duration of any topical decongestant should never exceed 3 days to prevent rhinitis medicamentosa (rebound congestion). 14

Obstructive Sleep Apnea Considerations

• Obstructive sleep apnea affects 50‑75 % of individuals with Down syndrome due to mid‑face hypoplasia, macroglossia, and hypotonia; effective nasal decongestion is therefore essential to mitigate nocturnal airway obstruction. 14

Medication Avoidance Recommendations

• Oral phenylephrine should be avoided because it undergoes extensive gut metabolism and has questionable efficacy even in individuals without Down syndrome. 14
• All over‑the‑counter cough and cold medications should be avoided in children with Down syndrome younger than 6 years, given the lack of proven benefit and the risk of toxicity. 14

Special Precautions for Patients with Congenital Heart Disease

• Prior to prescribing any sympathomimetic decongestant—whether oral or topical—patients with documented congenital heart disease must receive a cardiology consultation. 14

Intranasal Corticosteroids as First‑Line Therapy for Nasal Congestion in Elderly Patients

Efficacy of Intranasal Corticosteroids

• Intranasal corticosteroids (e.g., mometasone furoate, fluticasone propionate) effectively control all four major nasal symptoms—congestion, rhinorrhea, sneezing, and itching—more than any other medication class, including combinations of oral antihistamines and leukotriene antagonists, in elderly patients with nasal congestion. 15

Safety Considerations

• First‑generation oral antihistamines produce marked sedation and anticholinergic effects that are especially hazardous in the elderly, and therefore should be avoided in this population. 16

Adjunctive Short‑Term Topical Decongestant Use

• In elderly patients with severe obstruction that limits steroid delivery, a brief (≤ 3 days) course of topical oxymetazoline applied first, followed 5 minutes later by an intranasal corticosteroid, provides rapid symptom relief without inducing rebound congestion when the steroid is continued for 2–4 weeks, provided the patient has no significant cardiovascular disease. 17

Management of Severe Nasal Congestion in Elderly Patients with Viral Upper Respiratory Infection

Pharmacologic Therapy

• Intranasal corticosteroid therapy (mometasone furoate 200 µg twice daily) significantly improves nasal symptoms in patients with post‑viral acute rhinosinusitis compared with placebo and oral amoxicillin, while showing comparable safety profiles. (Evidence from a randomized controlled trial) 18

• A treatment course of intranasal corticosteroids for 2–4 weeks provides incremental symptom reduction, with the greatest benefit observed after approximately 15 days of use. (Level A evidence) 19

Adjunctive Measures

• Nasal saline irrigation offers additional symptomatic relief with minimal risk of adverse effects in viral upper respiratory infections. (Supported by the American Academy of Otolaryngology‑Head and Neck Surgery) 19

• Acetaminophen or ibuprofen are appropriate for managing pain and fever associated with viral upper respiratory infection. (Supported by the American Academy of Otolaryngology‑Head and Neck Surgery) 19

Antibiotic Stewardship

• Antibiotics (e.g., amoxicillin) provide no clinical benefit for viral upper respiratory infections and are associated with adverse events such as rash, gastrointestinal upset, and the promotion of antimicrobial resistance. (Guideline recommendation) 19

Expected Clinical Course

• The majority of patients experience symptomatic improvement within 7 days, and about 90 % are cured or markedly improved by day 15. (Observational data) 19

Follow‑Up Recommendations

• Patients should be instructed to seek medical review if symptoms worsen or persist beyond 2 weeks, as this may indicate progression to bacterial rhinosinusitis requiring alternative management. (Clinical guidance) 20